Clinical trials: Levodopa
Parkinson's Disease
A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients
To investigate the safety of once-daily repeated transdermal administration of SPM 962 within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's disease (PD) patients treated concomitantly with L-dopa in…
- Trial name
- NCT01631825
- Testing
- SPM 962
- Where
- 8 sites in Japan
- Volunteers
- 321 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Parkinson Disease, Orthostatic Hypotension
Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease
Levodopa is a precursor of dopamine and is the treatment of choice to treat the motor symptoms of Parkinson's disease (PD); however, the effect of levodopa on cardiovascular autonomic function in PD is poorly understood.
- Trial name
- NCT05487300
- Testing
- Autonomic testing on and off levodopa
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Utah
Parkinson Disease
A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period
The objective of this trial is to investigate the safety, tolerability, trough plasma concentration, and efficacy of pramipexole ER in comparison with those of pramipexole IR administrated orally for 12 weeks in patients with PD…
- Trial name
- NCT00560508
- Testing
- Pramipexole Immediate Release, Pramipexole Extended Release
- Where
- 19 sites in Japan
- Volunteers
- 112 people
- Sponsor
- Boehringer Ingelheim
Retinitis Pigmentosa
Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa
The purpose of this study is to evaluate the effect of L-Dopa on the progression of retinitis pigmentosa.
- Trial name
- NCT02837640
- Testing
- levodopa-carbidopa
- Where
- Lebanon
- Volunteers
- 50 people
- Sponsor
- Beirut Eye Specialist Hospital
Angelman Syndrome
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome
The purpose of this study is to evaluate the safety and effectiveness (how well a drug works) of Carbidopa/levodopa (Sinemet) in individuals with Angelman syndrome.
- Trial name
- NCT03235037
- Testing
- Levodopa
- Volunteers
- 10 people
- Sponsor
- Bennett Lavenstein
Parkinson's Disease
A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients
The primary objective of this study is to investigate safety of SPM 962 in advanced PD patients in a multi-center, open-label, non-controlled study following once-daily multiple transdermal doses of SPM962 within a range of 4.5…
- Trial name
- NCT01631812
- Testing
- SPM 962
- Where
- 7 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Angelman Syndrome
A Trial of Levodopa in Angelman Syndrome
This study is designed to determine whether levodopa will lead to an improvement in the development and tremor in children with Angelman syndrome (AS).
- Trial name
- NCT01281475
- Testing
- Levodopa
- Where
- 7 sites in United States
- Volunteers
- 67 people
- Sponsor
- Wen-Hann Tan
Parkinson's Disease, Helicobacter Infections
Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
The purpose of this study is to determine whether treatment of H. pylori (an infection of the stomach) improves treatment effectiveness in patients with Parkinson's disease and motor fluctuations.
- Conditions
- Parkinson's Disease, Helicobacter Infections, Motor Fluctuations
- Trial name
- NCT00664209
- Testing
- clartihromycin, amoxicillin, and omeprazole
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, Los Angeles
Amblyopia
Levodopa for the Treatment of Residual Amblyopia
The purpose of this study is to evaluate the efficacy and safety of oral levodopa and patching versus oral placebo and patching as treatment for residual amblyopia in children 7 to <13 years old with visual acuity of 20/50 to…
- Trial name
- ATS17 (NCT01190813)
- Testing
- Levodopa/Carbidopa, Patching
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- Jaeb Center for Health Research
Parkinson Disease
JP-1730 to Treat Parkinson's Disease
This study will evaluate the effects of an experimental drug called JP-1730 on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term treatment with levodopa.
- Trial name
- NCT00040209
- Testing
- JP 1730, IV Levodopa, IV Apomorphine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic
Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.
This study is aimed at patients with multi-system atrophy - parkinsonian type (P-MSA) or Parkinson's disease (PD) receiving dopaminergic drugs and suffering from orthostatic hypotension (OH).
- Conditions
- Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic, Parkinson Disease
- Trial name
- CARBIDOH (NCT06831500)
- Testing
- Administration of Carbidopa/levodopa
- Where
- 2 sites in Switzerland
- Volunteers
- 36 people
- Sponsor
- Julien Bally
Response to Levodopa, Motor Outcomes
Effects of Helicobacter Pylori Infection Eradication in Patients With Parkinson's Disease
A higher prevalence of Helicobacter pylori infection rate has been demonstrated among PD patients compared to controls. As H. pylori infection is known to interfere with levodopa absorption, we embarked on this is a study to…
- Conditions
- Response to Levodopa, Motor Outcomes, Quality of Life Outcomes
- Trial name
- NCT02112812
- Testing
- Eradication therapy for H.pylori infection, Eradication of Helcobacter Pylori, Eradication therapy for Helicobacter pylori
- Where
- Malaysia
- Volunteers
- 82 people
- Sponsor
- National University of Malaysia
Dyskinesias, Parkinson Disease
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
This study is to evaluate long-term safety, tolerability and efficacy for AFQ056 in patients who have completed an AFQ056A study in Parkinson's disease L-dopa induced dyskinesias (PD-LID).
- Conditions
- Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders
- Trial name
- NCT01491932
- Testing
- AFQ056
- Where
- 32 sites in United States, Austria and 8 more
- Volunteers
- 129 people
- Sponsor
- Novartis Pharmaceuticals
Oxytocin Group, L-DOPA Group
Oxytocin and Dopamine's Effect on Vicarious Optimism
To investigate the effect of intranasal Oxytocin and L-DOPA's effect on vicarious optimism.
- Conditions
- Oxytocin Group, L-DOPA Group, Placebo Group
- Trial name
- NCT03891095
- Testing
- Oxytocin, L-DOPA
- Where
- China
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Beijing Normal University
Congenital Hyperinsulinism
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
The goal of this project is to determine the role of FDOPA/PET as a pre-operative diagnostic imaging procedure for differentiating focal and diffuse forms of congenital hyperinsulinism and locating focal lesions in the pancreas…
- Trial name
- DOPA PET (NCT04205604)
- Testing
- 18F-Fluoro Dopa Imaging
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Miguel Pampaloni
Parkinson's Disease
Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics
The main treatment for Parkinson's disease is a medication called levodopa. Levodopa has to be absorbed from the gut and travel to the brain to work, but a naturally occurring enzyme in the lining of the stomach, called dopamine…
- Trial name
- NCT07793461
- Testing
- Levodopa (L-dopa)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Beth Israel Deaconess Medical Center
Parkinson's Disease
KW-6002 to Treat Parkinson's Disease
This study will evaluate the effects of an experimental drug called KW-6002 on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term treatment with levodopa.
- Trial name
- NCT00006337
- Testing
- KW-6002, IV Levodopa
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson's Disease
Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease
This study will evaluate the effects of an experimental drug called NS2330 on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term treatment with levodopa.
- Trial name
- NCT00006077
- Testing
- NS2330, Levodopa and Domperidone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Dyskinesias, Parkinson Disease
Study of LY300164 for the Treatment of Parkinson's Disease
This study will test the effectiveness of an experimental drug called LY300164 on improving Parkinson's disease symptoms, such as movement impairments and tremor, as well as involuntary movements produced by long-term treatment…
- Trial name
- NCT00004576
- Testing
- LY300164
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Parkinson Disease
Udall Project 2 Aim 2A&C
This protocol will leverage the novel (on-label, FDA-approved) local field potential measuring capability of the Medtronic Percept™ PC or RC DBS system to study the effects of globus pallidus internus, globus pallidus externus…
- Trial name
- NCT05656586
- Testing
- observational-- no intervention
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Minnesota